Wave Life Sciences Stock Forecast, Price & News

+0.07 (+0.97 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume430,971 shs
Average Volume825,213 shs
Market Capitalization$364.45 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Wave Life Sciences logo

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.80 out of 5 stars

Medical Sector

199th out of 2,100 stocks

Pharmaceutical Preparations Industry

95th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

Is Wave Life Sciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Wave Life Sciences stock.
View analyst ratings for Wave Life Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Wave Life Sciences?

Wall Street analysts have given Wave Life Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Wave Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Wave Life Sciences?

Wave Life Sciences saw a decline in short interest in May. As of May 28th, there was short interest totaling 2,970,000 shares, a decline of 21.2% from the May 13th total of 3,770,000 shares. Based on an average daily trading volume, of 957,300 shares, the short-interest ratio is currently 3.1 days. Approximately 8.7% of the shares of the stock are sold short.
View Wave Life Sciences' Short Interest

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Wave Life Sciences

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.86) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.30. Wave Life Sciences had a negative net margin of 746.67% and a negative trailing twelve-month return on equity of 242.12%.
View Wave Life Sciences' earnings history

How has Wave Life Sciences' stock been impacted by COVID-19?

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, WVE stock has decreased by 10.0% and is now trading at $7.31.
View which stocks have been most impacted by COVID-19

What price target have analysts set for WVE?

4 analysts have issued 12-month price objectives for Wave Life Sciences' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Wave Life Sciences' share price to reach $12.00 in the next year. This suggests a possible upside of 64.2% from the stock's current price.
View analysts' price targets for Wave Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the following people:
  • Dr. Paul B. Bolno M.B.A., M.D., MBA, Pres, CEO & Director (Age 47, Pay $961.47k)
  • Dr. Chandra Vargeese, Chief Technology Officer (Age 60, Pay $619.2k)
  • Dr. Michael A. Panzara M.P.H., M.D., MPH, Chief Medical Officer and Head of Therapeutics Discovery & Devel. (Age 54, Pay $655k)
  • Mr. Kyle B. Moran, CFO & Principal Accounting Officer (Age 50)
  • Kate Rausch, Head of Investor Relations
  • Ms. Linda Rockett J.D., Gen. Counsel
  • Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 43)
  • Mr. Jonathan Rosin, Chief HR Officer
  • Mr. Jose Juves, Sr. VP of Corp. Affairs & Patient Advocacy
  • Dr. Kenneth Rhodes, Sr. VP of Therapeutics Discovery

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences CEO Paul Bolno, M.D., MBA on Paul Bolno, M.D., MBA has an approval rating of 92% among Wave Life Sciences' employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Wave Life Sciences' key competitors?

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (9.36%), Deerfield Management Company L.P. Series C (7.03%), Maverick Capital Ltd. (6.18%), BlackRock Inc. (5.98%), Nantahala Capital Management LLC (5.78%) and JPMorgan Chase & Co. (2.58%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno.
View institutional ownership trends for Wave Life Sciences

Which major investors are selling Wave Life Sciences stock?

WVE stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, Nantahala Capital Management LLC, D. E. Shaw & Co. Inc., Barclays PLC, Voloridge Investment Management LLC, Goldman Sachs Group Inc., and Man Group plc.
View insider buying and selling activity for Wave Life Sciences
or view top insider-selling stocks.

Which major investors are buying Wave Life Sciences stock?

WVE stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Maverick Capital Ltd., Point72 Asset Management L.P., Primecap Management Co. CA, Altium Capital Management LP, JPMorgan Chase & Co., Dimensional Fund Advisors LP, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Wave Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $7.31.

How much money does Wave Life Sciences make?

Wave Life Sciences has a market capitalization of $364.45 million and generates $20.08 million in revenue each year. The company earns $-149,910,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis.

How many employees does Wave Life Sciences have?

Wave Life Sciences employs 217 workers across the globe.

What is Wave Life Sciences' official website?

The official website for Wave Life Sciences is

Where are Wave Life Sciences' headquarters?

Wave Life Sciences is headquartered at 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at (656) 236-3388 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.